DOI: 10.12890/2024_004782
Oxaliplatin-induced immune thrombocytopenia in a patient with pancreatic cancer
Authors
senturk96mustafa@hotmail.com
Keywords
Oxaliplatin, oxalipatin-induced immune thrombocytopenia, thrombocytopeniaAbstract
Oxaliplatin-induced immune thrombocytopenia is a rare but potentially serious complication of chemotherapy. We present the case of a 55-year-old man with stage 4 pancreatic carcinoma who developed immune thrombocytopenia during the 18th cycle of folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) chemotherapy, immediately after oxaliplatin infusion. Despite treatment with methylprednisolone and platelet infusion, the patient’s platelet count remained low. Subsequent plasmapheresis and continued steroid therapy resulted in a gradual improvement in platelet count and resolution of symptoms. This case highlights the importance of considering immune thrombocytopenia in patients receiving oxaliplatin-based chemotherapy, and the potential role of plasmapheresis in refractory cases. Further research is needed to elucidate the optimal management of this rare complication.
References
- Bano N, Najam R, Qazi F, Mateen A. Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches. Asian Pac J Cancer Prev 2016;17:1637-1641.
- Chen VM, Thrift KM, Morel-Kopp MC, Jackson D, Ward CM, Flower RL. An immediate hemolytic reaction induced by repeated administration of oxaliplatin. Transfusion 2004;44:838-843.
- Akdeniz A, Kucukoztas N, Yalcin S, Akcali Z, Altundag O. Oxaliplatin-induced immune thrombocytopenia in a patient with colon cancer. Am Surg 2011;77:E9.
- Curtis BR, Hsu YS, Podoltsev N, Lacy J, Curtis S, Samuel MS, et al. Patients treated with oxaliplatin are at risk for thrombocytopenia caused by multiple drug-dependent antibodies. Blood 2018;131:1486-1489.
- James E, Podoltsev N, Salehi E, Curtis BR, Saif MW. Oxaliplatin-induced immune thrombocytopenia: another cumulative dose-dependent side effect. Clin Colorectal Cancer 2009;8:220-224.
- Taleghani BM, Meyer O, Fontana S, Ahrens N, Novak U, Borner MM, et al. Oxaliplatin-induced immune pancytopenia. Transfusion 2005;45:704-708.
- Beg MS, Komrokji RS, Ahmed K, Safa MM. Oxaliplatin-induced immune mediated thrombocytopenia. Cancer Chemother Pharmacol 2008;62:925-927.
- Bencardino K, Mauri G, Amatu A, Tosi F, Bonazzina E, Palmeri L, et al. Oxaliplatin Immune-Induced Syndrome Occurs With Cumulative Administration and Rechallenge: Single Institution Series and Systematic Review Study. Clin Colorectal Cancer 2016;15:213-221.
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-245.
